ColoAlert
Description
ColoAlert is Europe’s first genetic colorectal cancer screening test. By directly detecting tumour cells within a stool sample, for the first time sensitivity is – in combination with the incorporated occult blood analysis – increased to 85 % without missing the recommended minimum specificity of 90 % for screening programmes. Patients easily withdraw their sample within 5 minutes with the test kit and receive their lab report after a few days – comfortably and discretely at home.
Winner
Excellence in Business to Consumer
Medical & Health Company PharmGenomics GmbH Development PharmGenomics GmbH Share
Medical & Health Company PharmGenomics GmbH Development PharmGenomics GmbH Share